C2 Therapeutics raised $11.6 million in equity funding, according to a recent regulatory filing.
The cash infusion comes just 2 months after the company received FDA clearance for its ablation device to treat a pre-cancerous condition known as Barrett’s esophagus.
People afflicted with Barrett’s esophagus – a condition in which in the tissue lining the throat is replaced by tissue similar to that found in the intestinal lining – are at increased risk for cancer. The condition is often associated with gastric reflex disease, or GERD.
Help employers find you! Check out all the jobs and post your resume.
